Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2004-10-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1073/PNAS.0404874101PMID 15306684PMCID PMC521993
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• "Curing MS: How Science Is Solving the Mysteries of Multiple Sclerosis".

  2005cited by this paper
• Expansion and Functional Relevance of High-Avidity Myelin-Specific CD4+ T Cells in Multiple Sclerosis

  2004cited by this paper
• Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis

  2004cited by this paper
• Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo.

  2004cited by this paper
• Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis1

  2004cited by this paper
• Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion

  2004cited by this paper
• Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate.

  2004cited by this paper
• Curing MS: How Science Is Solving the Mysteries of Multiple Sclerosis

  2004cited by this paper
• Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood.

  2004cited by this paper
• Pathogenesis of multiple sclerosis: The eyes only see what the mind is prepared to comprehend

  2004cited by this paper
• T-cell vaccination in multiple sclerosis.

  2004cited by this paper
• Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.

  2003cited by this paper
• The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system.

  2003cited by this paper
• Regulatory lymphocytes: Regulatory T cells under scrutiny

  2003cited by this paper
• Regulatory lymphocytes: Antigen-induced regulatory T cells in autoimmunity

  2003cited by this paper
• T cell vaccination in multiple sclerosis patients with autologous CSF‐derived activated T cells: results from a pilot study

  2003cited by this paper
• Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year

  2003cited by this paper
• T-cell-mediated autoimmunity: novel techniques to characterize autoreactive T-cell receptors.

  2003cited by this paper
• Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells1

  2003cited by this paper
• Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.

  2003cited by this paper
• Immunity

  2003cited by this paper
• From Proteins and Protein Models to Their Use in Immunology and Immunotherapy

  2003cited by this paper
• Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases

  2003cited by this paper
• Aire regulates negative selection of organ-specific T cells

  2003cited by this paper
• New and emerging treatment options for multiple sclerosis.

  2003cited by this paper
• Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis

  2003cited by this paper
• Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ

  2003cited by this paper
• T-cell-antigen recognition and the immunological synapse

  2003cited by this paper
• Single-Cell Repertoire Analysis Demonstrates that Clonal Expansion Is a Prominent Feature of the B Cell Response in Multiple Sclerosis Cerebrospinal Fluid 1

  2003cited by this paper
• Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.

  2002cited by this paper
• Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.

  2002cited by this paper
• A functional and structural basis for TCR cross-reactivity in multiple sclerosis

  2002cited by this paper
• MRI techniques to monitor MS evolution: The present and the future

  2002cited by this paper
• Autoantigen microarrays for multiplex characterization of autoantibody responses

  2002cited by this paper
• Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand.

  2002cited by this paper
• Antibody‐mediated suppression of Vβ5.2/5.3+ T cells in multiple sclerosis: Results from an MRI‐monitored phase II clinical trial

  2002cited by this paper
• New concepts in the immunopathogenesis of multiple sclerosis

  2002cited by this paper
• T cell vaccination in multiple sclerosis: results of a preliminary study

  2002cited by this paper
• Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases.

  2002cited by this paper
• BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

  2002cited by this paper
• Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis

  2002cited by this paper
• Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients.

  2002cited by this paper
• CD4+CD28- costimulation-independent T cells in multiple sclerosis.

  2001cited by this paper
• Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosis

  2001cited by this paper
• Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis.

  2001cited by this paper
• Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates

  2001cited by this paper
• TCR Peptide Therapy in Human Autoimmune Diseases

  2001cited by this paper
• Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone.

  2001cited by this paper
• Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway.

  2001cited by this paper
• A Pathogenic Role for Myelin-Specific Cd8+ T Cells in a Model for Multiple Sclerosis

  2001cited by this paper
• Immunotherapy of multiple sclerosis: Where are we? Where should we go?

  2001cited by this paper
• Mechanisms of action of glatiramer acetate in multiple sclerosis

  2001cited by this paper
• Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells.

  2001cited by this paper
• Myelin Antigen-Specific CD8+ T Cells Are Encephalitogenic and Produce Severe Disease in C57BL/6 Mice1

  2001cited by this paper
• Anti‐inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration

  2001cited by this paper
• Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis.

  2001cited by this paper
• Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.

  2001cited by this paper
• Regulatory T cells in spontaneous autoimmune encephalomyelitis

  2001cited by this paper
• Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

  2001cited by this paper
• Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

  2001cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand

  2000cited by this paper
• The role of B cells and autoantibodies in multiple sclerosis

  2000cited by this paper
• Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen.

  2000cited by this paper
• Myelin oligodendrocyte glycoprotein‐DNA vaccination induces antibody‐mediated autoaggression in experimental autoimmune encephalomyelitis

  2000cited by this paper
• Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination

  2000cited by this paper
• Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients1

  2000cited by this paper
• Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.

  2000cited by this paper
• Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

  2000cited by this paper
• Multiple sclerosis.

  2000cited by this paper
• Oral tolerance, an active immunologic process mediated by multiple mechanisms.

  2000cited by this paper
• Specific immunotherapy: One size does not fit all

  2000cited by this paper
• NBI‐5788, an altered MBP83‐99 peptide, induces a T‐helper 2–like immune response in multiple sclerosis patients

  2000cited by this paper
• A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

  2000cited by this paper
• Mechanisms of immunomodulation by glatiramer acetate

  2000cited by this paper
• Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

  2000cited by this paper
• Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

  2000cited by this paper
• Preferential Recognition of TCR Hypervariable Regions by Human Anti-Idiotypic T Cells Induced by T Cell Vaccination1

  2000cited by this paper
• Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed [with a hedge on this bet].

  2000cited by this paper
• Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction

  2000cited by this paper
• T cell vaccination in secondary progressive multiple sclerosis.

  2000cited by this paper
• Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.

  2000cited by this paper
• Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence.

  2000cited by this paper
• Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations.

  2000cited by this paper
• Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP85VVHFFKNIVTP96RT in multiple sclerosis patients

  2000cited by this paper
• Molecular mimicry and multiple sclerosis: Degenerate T‐cell recognition and the induction of autoimmunity

  1999cited by this paper
• Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy

  1999cited by this paper
• Autoimmune Disease: Modulation of T Cell Encoding a Self-Peptide Prevents Suppressive Immunization with DNA

  1999cited by this paper
• Candidate autoantigens in multiple sclerosis

  1999cited by this paper
• A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor

  1999cited by this paper
• Concepts of viral pathogenesis of multiple sclerosis.

  1999cited by this paper
• Gene transfer into CD4+ T lymphocytes: Green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses

  1999cited by this paper
• Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.

  1999cited by this paper
• B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions.

  1999cited by this paper
• Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

  1999cited by this paper
• TNF neutralization in MS

  1999cited by this paper
• Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7.

  1999cited by this paper
• Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1.

  1998cited by this paper
• Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis.

  1998cited by this paper
• T cell vaccination induces T cell receptor Vbeta-specific Qa-1-restricted regulatory CD8(+) T cells.

  1998cited by this paper

• The JAK-STAT signaling pathway in inflammatory and autoimmune diseases: Its potential role as a therapeutic target.

  2026cites this paper
• Mitochondrial and metabolic dysfunction of peripheral immune cells in multiple sclerosis

  2024cites this paper
• Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials

  2024cites this paper
• A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments

  2023cites this paper
• iPSC-derived reactive astrocytes from patients with multiple sclerosis protect cocultured neurons in inflammatory conditions

  2023cites this paper
• Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery

  2022cites this paper
• Epstein-Barr virus antibody in newly diagnosed multiple sclerosis patients and its association with relapse severity and lesion location.

  2022cites this paper
• Literatur

  2022cites this paper
• Astrocytes in Multiple Sclerosis—Essential Constituents with Diverse Multifaceted Functions

  2021cites this paper
• Combination of Probiotics and Natural Compounds to Treat Multiple Sclerosis via Warburg Effect

  2021cites this paper
• The Cross Talk between Underlying Mechanisms of Multiple Sclerosis and Epilepsy May Provide New Insights for More Efficient Therapies

  2021cites this paper
• Role of tissue Transglutaminase in glial cell processes involved in multiple sclerosis

  2020cites this paper
• Extracellular vesicles in neurodegenerative disorders

  2020cites this paper
• Molecular Interventions towards Multiple Sclerosis Treatment

  2020influential citation
• Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer’s Disease, Lithium, and Autophagy

  2020cites this paper
• Knowledge Management approaches to model pathophysiological mechanisms and discover drug targets in Multiple Sclerosis

  2019cites this paper
• Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis

  2019cites this paper
• Circulating Picomolar Levels of CCL2 Downregulate Ongoing Chronic Experimental Autoimmune Encephalomyelitis by Induction of Regulatory Mechanisms

  2019cites this paper
• Inflammasome Proteins As Biomarkers of Multiple Sclerosis

  2018influential citation
• Brain Morphometry in Multiple Sclerosis

  2018cites this paper
• Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches

  2018cites this paper
• Aktuelle Therapiemöglichkeiten der Multiplen Sklerose // Therapy options of multiple sclerosis

  2018cites this paper
• The effect of disease modifying therapies on CD62L expression in multiple sclerosis

  2018cites this paper
• Multiple sclerosis – an overview on epidemiology, pathogenesis and diagnosis

  2017cites this paper
• MULTIPLE SCLEROSIS: AN INSIGHT INTO EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE)

  2017cites this paper
• The early diagnosis and treatments in multiple sclerosis

  2017cites this paper
• Iron‐sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia

  2017influential citation
• Immunomodulatory effects of glatiramer acetate as they relate to stage-specific immune dysregulation in multiple sclerosis.

  2016cites this paper
• 多発性硬化症における免疫病態とグラチラマー酢酸塩（コパキソン®皮下注20 mgシリンジ）の免疫調整作用

  2016cites this paper
• Epitope mapping of anti‐myelin oligodendrocyte glycoprotein (MOG) antibodies in a mouse model of multiple sclerosis: microwave‐assisted synthesis of the peptide antigens and ELISA screening

  2016cites this paper
• Immunomodulation of Glatiramer Acetate in Multiple Sclerosis

  2016cites this paper
• Computational modeling of brain pathologies: the case of multiple sclerosis

  2016cites this paper
• Robust Edge Detection Applied to Multi-Parametric Magnetic Resonance Images

  2016cites this paper
• The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets.

  2016cites this paper
• "Oral Dimethyl Fumarate (BG-12; Tecfidera®) for Multiple Sclerosis."

  2016cites this paper
• Proteomic profile of cerebrospinal fluid in patients with multiple sclerosis using two dimensional gel electrophoresis

  2016cites this paper
• Demyelination patterns in a mathematical model of multiple sclerosis

  2016cites this paper
• Live Analysis of the Role of B cells in Experimental Autoimmune Encephalomyelitis

  2016cites this paper
• Further understanding of the immunopathology of multiple sclerosis: impact on future treatments

  2016cites this paper
• Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications

  2015cites this paper
• Neurobehavioral burden of multiple sclerosis with nanotheranostics

  2015cites this paper
• Die Bedeutung der N-Glykosylierung von T-Zell Populationen in der Experimentellen Autoimmunen Enzephalomyelitis

  2015cites this paper
• Clinical and experimental studies of multiple sclerosis in Russia: experience of the leading national research centers

  2015cites this paper
• Cues Guiding Leukocyte Transendothelial Migration across the Blood-Brain Barrier in Neuroinflammation: Endothelial Heterogeneity, Chemokines, and Extracellular Vesicles

  2015cites this paper
• Copy number variations in multiple sclerosis and neuromyelitis optica

  2015cites this paper
• mixed-isotype heterodimer in the pathogenesis of ‘ humanized ’ multiple sclerosis-like disease Running Title : Potential effect on MS from DQA 1 * 01 : 02 ; DRB 1 * 15 : 01

  2015cites this paper
• Bone Marrow Mesenchymal Stromal Cells Isolated from Multiple Sclerosis Patients have Distinct Gene Expression Profile and Decreased Suppressive Function Compared with Healthy Counterparts

  2015cites this paper
• Progressive multiple sclerosis 1 Pathological mechanisms in progressive multiple sclerosis

  2015cites this paper
• αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell–related features

  2015cites this paper
• Kapitel 19 – Neue, experimentelle und zukünftige Therapieansätze

  2015cites this paper
• Pathological mechanisms in progressive multiple sclerosis.

  2015cites this paper
• An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis.

  2015cites this paper
• Autoimmune encephalitis in humans: how closely does it reflect multiple sclerosis ?

  2015cites this paper
• Reverse translation of failed treatments can help improving the validity of preclinical animal models.

  2015cites this paper
• The role of activated microglia in multiple sclerosis and clinically isolated syndromes : neuroimaging studies

  2015cites this paper
• Role of a Novel Human Leukocyte Antigen-DQA1*01:02;DRB1*15:01 Mixed Isotype Heterodimer in the Pathogenesis of “Humanized” Multiple Sclerosis-like Disease*

  2015cites this paper
• Unaltered regulatory B-cell frequency and function in patients with multiple sclerosis.

  2014cites this paper
• Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b

  2014cites this paper
• Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.

  2014cites this paper
• Teriflunomide and Its Mechanism of Action in Multiple Sclerosis

  2014influential citation
• Demyelination in multiple sclerosis

  2014cites this paper
• Autoantibodies to Glutamate Receptor Antigens in Multiple Sclerosis and Rasmussen's Encephalitis

  2014cites this paper
• Ephrine und Eph-Rezeptoren in der Pathogenese der Multiplen Sklerose und der Experimentellen Autoimmunen Enzephalomyelitis

  2014cites this paper
• Multiple Sclerosis: Impact on Functioning of the Blood–Brain Barrier

  2014cites this paper
• P-glycoprotein regulates trafficking of CD8+ T cells to the brain parenchyma

  2014cites this paper
• Mechanism of multiple sclerosis based on the clinical trial results of molecular targeted therapy

  2014cites this paper
• Neue Behandlungsziele bei Multipler Sklerose: Mögliche neuroprotektive Aspekte etablierter und neuer Immuntherapeutika

  2014cites this paper
• Neurodegenerative Mechanisms of Multiple Sclerosis

  2014influential citation
• A molecular view of multiple sclerosis and experimental autoimmune encephalitis: what can we learn from the epitope data?

  2014cites this paper
• Antigen-based immunotherapy for autoimmune disease: current status

  2014cites this paper
• Antigen-based immunotherapy for autoimmune disease : current status

  2014cites this paper
• The Retrovirus/Superantigen Hypothesis of Multiple Sclerosis

  2014cites this paper
• [Epstein-Barr virus in the pathogenesis of multiple sclerosis (a review)].

  2014cites this paper
• Glial cells as progenitors and stem cells: new roles in the healthy and diseased brain.

  2014cites this paper
• Evaluation of the implication of KIR2DL2 receptor in multiple sclerosis and herpesvirus susceptibility.

  2014cites this paper
• Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up

  2014cites this paper
• Mode of action and clinical studies with fumarates in multiple sclerosis.

  2014cites this paper
• Liposome-encapsulated peptides protect against experimental allergic encephalitis

  2013influential citation
• Mechanisms of disease progression

  2013cites this paper
• MicroRNA Regulation in Multiple Sclerosis

  2013cites this paper
• Análise da expressão gênica por microarrays de células-tronco hematopoéticas e mesenquimais de pacientes com esclerose múltipla

  2013cites this paper
• New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis

  2013cites this paper
• Advancing therapeutic options in multiple sclerosis with neuroprotective properties

  2013cites this paper
• The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications

  2013cites this paper
• The plasminogen activator system: involvement in central nervous system inflammation and a potential site for therapeutic intervention

  2013cites this paper
• Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.

  2013cites this paper
• Induction of Experimental Autoimmune Encephalomyelitis With Recombinant Human Myelin Oligodendrocyte Glycoprotein in Incomplete Freund’s Adjuvant in Three Non-human Primate Species

  2013cites this paper
• Cognitive and neuropsychiatric disease manifestations in MS.

  2013cites this paper
• Improving the motor and cognitive performance among multiple sclerosis patients through the use of mental imagery

  2013cites this paper
• Immunopharmacological consequences of immune responses to therapeutic interferon beta

  2013cites this paper
• Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.

  2013cites this paper
• Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics

  2013cites this paper
• Retrovirus-Superantigen-Hypothese der Multiplen Sklerose

  2013cites this paper
• Antigen-Specific Tolerance by Autologous Myelin Peptide–Coupled Cells: A Phase 1 Trial in Multiple Sclerosis

  2013cites this paper
• Effektivität und Nebenwirkungen von Mitoxantron bei Multipler Sklerose in einer Langzeitbeobachtung über 10 Jahre

  2013cites this paper
• The Blood–Brain Barrier in Neuroinflammation

  2013cites this paper
• Helminth therapy and multiple sclerosis.

  2013cites this paper
• In vitro assessment of mesenchymal stem cells immunosuppressive potential in multiple sclerosis patients.

  2013cites this paper
• This information is current as Autoimmune Encephalomyelitis Severity of Relapsing Experimental Plasmacytoid Dendritic Cells Regulate the Cutting Edge: Central Nervous System

  2013cites this paper
• Development of resistance to biologic therapies with reference to IFN-β.

  2012cites this paper